The aim of this study, which is based on a translationally edged clinical trial, was to assess potential statin-induced changes in cholesterol levels and the expression of LDLR in patient tumors combined with in vitro experiments on breast cancer cells, to gain an enhanced understanding of the role of the mevalonate pathway in cancer cholesterol metabolism. This evidence concerns the gene LDLR and breast cancer.